Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomedtracker’s Best Of J.P. Morgan: 15 Companies To Watch

Executive Summary

Highlights from Biomedtracker’s daily reports from the J.P. Morgan Healthcare Conference include products advancing in NASH, competition in CAR-T and more.

You may also be interested in...



Sage Says Brexanolone's SRSE Result Doesn't Mean PPD Studies Will Fail

The Phase III study for brexanolone in super-refractory status epilepticus did not meet its primary endpoint, but Sage is optimistic about the drug's prospects in postpartum depression and its earlier-stage SAGE-217.

Executives On The Move: New CEOs At Alentis Therapeutics, Melinta Therapeutics And NBE-Therapeutics

New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.

Cadila Pharma Launches Rituximab And Teriparatide Biosimilars In India

After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel